Cidara Therapeutics Inc (NASDAQ:CDTX) — Market Cap & Net Worth
Market Cap & Net Worth: Cidara Therapeutics Inc (CDTX)
Cidara Therapeutics Inc (NASDAQ:CDTX) has a market capitalization of $6.96 Billion ($6.96 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2868 globally and #1000 in its home market, demonstrating a 0.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cidara Therapeutics Inc's stock price $221.38 by its total outstanding shares 31446306 (31.45 Million). Analyse Cidara Therapeutics Inc (CDTX) cash flow conversion to see how efficiently the company converts income to cash.
Cidara Therapeutics Inc Market Cap History: 2015 to 2026
Cidara Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $10.79 Billion to $6.96 Billion (-2.85% CAGR).
Index Memberships
Cidara Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.29% | #59 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.02% | #320 of 3165 |
Weight: Cidara Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cidara Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cidara Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
662.96x
Cidara Therapeutics Inc's market cap is 662.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.42 Billion | $20.91 Million | -$41.09 Million | 115.47x | N/A |
| 2020 | $1.26 Billion | $12.07 Million | -$72.11 Million | 104.24x | N/A |
| 2021 | $798.74 Million | $49.57 Million | -$43.91 Million | 16.11x | N/A |
| 2022 | $475.66 Million | $64.29 Million | -$29.80 Million | 7.40x | N/A |
| 2023 | $499.37 Million | $23.28 Million | -$22.93 Million | 21.45x | N/A |
| 2024 | $845.28 Million | $1.27 Million | -$169.83 Million | 662.96x | N/A |
Competitor Companies of CDTX by Market Capitalization
Companies near Cidara Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cidara Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cidara Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cidara Therapeutics Inc's market cap moved from $10.79 Billion to $ 6.96 Billion, with a yearly change of -2.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.96 Billion | +0.22% |
| 2025 | $6.95 Billion | +721.76% |
| 2024 | $845.28 Million | +69.27% |
| 2023 | $499.37 Million | +4.98% |
| 2022 | $475.66 Million | -40.45% |
| 2021 | $798.74 Million | -36.50% |
| 2020 | $1.26 Billion | -47.92% |
| 2019 | $2.42 Billion | +63.40% |
| 2018 | $1.48 Billion | -65.44% |
| 2017 | $4.28 Billion | -34.62% |
| 2016 | $6.54 Billion | -39.39% |
| 2015 | $10.79 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Cidara Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.96 Billion USD |
| MoneyControl | $6.96 Billion USD |
| MarketWatch | $6.96 Billion USD |
| marketcap.company | $6.96 Billion USD |
| Reuters | $6.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more